NYXH logo

Nyxoah SA Stock Price

ENXTBR:NYXH Community·€179.2m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 7 Fair Values set on narratives written by author

NYXH Share Price Performance

€4.17
-3.62 (-46.47%)
€13.00
Fair Value
€4.17
-3.62 (-46.47%)
68.0% undervalued intrinsic discount
€13.00
Fair Value
Price €4.17
AnalystHighTarget €13.00
AnalystLowTarget €6.00
AnalystConsensusTarget €10.00

NYXH Community Narratives

AnalystHighTarget·
Fair Value €13 68.0% undervalued intrinsic discount

Minimally Invasive Devices Will Capture Expanding Sleep Market

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AnalystLowTarget·
Fair Value €6 30.6% undervalued intrinsic discount

Regulatory Delays Will Hinder Revenue Ramp But Allow Recovery

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·
Fair Value €10 58.4% undervalued intrinsic discount

FDA Approval And Expanding Network Will Grow US Sleep Market

0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative

Trending Discussion

Updated Narratives

NYXH logo

NYXH: U.S. Launch Execution Will Drive Constructive Long Term Upside

Fair Value: €13 68.0% undervalued intrinsic discount
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
NYXH logo

NYXH: U.S. Launch Progress Will Drive Momentum Amid Approval Challenges

Fair Value: €10 58.4% undervalued intrinsic discount
6 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
NYXH logo

Regulatory Delays Will Hinder Revenue Ramp But Allow Recovery

Fair Value: €6 30.6% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Excellent balance sheet and slightly overvalued.

2 Risks
2 Rewards

Nyxoah SA Key Details

€5.6m

Revenue

€2.0m

Cost of Revenue

€3.6m

Gross Profit

€87.4m

Other Expenses

-€83.7m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
-1.95
64.36%
-1,484.68%
37.4%
View Full Analysis

About NYXH

Founded
2009
Employees
184
CEO
Olivier Taelman
WebsiteView website
www.nyxoah.com

Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Recent NYXH News & Updates

Recent updates

No updates